Eric Carlson, MD
Interventional Cardiology · Greenville, NCNPI 1316941206
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,075 of the $26,331 with a category attached, or 64.8%. Boston Scientific accounts for 78.4% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2022 at $9,450 and has fallen 98.7% since, to $123 in 2024.
Across 267 payments — averaging $98.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$21K
- Abbott$3K
- E.r. Squibb & Sons, L.L.C.$397
- Biotronik Inc.$236
- Novartis$152
- GE HealthCare$148
- plus $1K from 26 others
Across 34 payments — averaging $2158.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$73K
What the payments were for
- Consulting fees$17,07565%
- Travel & lodging$3,01711%
- Food & beverage$5,96323%
- Education$2761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 40 | $20,641 |
| Abbott | 74 | $3,335 |
| E.r. Squibb & Sons, L.L.C. | 53 | $397 |
| Biotronik Inc. | 6 | $236 |
| Novartis | 11 | $152 |
| GE HealthCare | 1 | $148 |
| Johnson & Johnson | 6 | $148 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $144 |
| Sanofi-aventis U.S. LLC | 7 | $122 |
| AstraZeneca | 9 | $122 |
| Abiomed | 2 | $104 |
| Pfizer | 6 | $96 |
| Irhythm Technologies, Inc. | 2 | $83 |
| Novo Nordisk | 5 | $79 |
| Amarin Pharma, Inc. | 6 | $79 |
| Baxter Healthcare | 3 | $68 |
| Amgen | 3 | $44 |
| Gilead | 3 | $44 |
| Medtronic | 2 | $35 |
| Lundbeck LLC | 2 | $30 |
| AVEO Pharmaceuticals, Inc. | 1 | $30 |
| Astellas Pharma US Inc | 2 | $26 |
| Karyopharm Therapeutics Inc. | 1 | $26 |
| Shockwave Medical, Inc | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| Beigene USA, Inc. | 1 | $19 |
| Infobionic, Inc | 1 | $15 |
| Edwards Lifesciences | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$8,146
- Watchman$4,000
- CARDIOMEMS$1,575
- AMS$324
- Mitra Clip system$122
How this compares
$26,331 in reported general payments places this provider in the 80th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 170 | $104,970 |
| BrilintaTicagrelor | 116 | $70,744 |
| EntrestoSacubitril/Valsartan | 81 | $62,448 |
| Repatha SureclickEvolocumab | 50 | $30,836 |
| FarxigaDapagliflozin Propanediol | 18 | $12,025 |
| Prasugrel Hcl | 27 | $3,909 |
| Ranolazine ErRanolazine | 88 | $3,301 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 13 | $2,117 |
| ClopidogrelClopidogrel Bisulfate | 185 | $1,658 |
| Atorvastatin Calcium | 188 | $1,652 |
| Metoprolol Succinate | 192 | $1,500 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 42 | $750 |
| Bumetanide | 21 | $665 |
| Pravastatin Sodium | 39 | $653 |
| Carvedilol | 98 | $629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $96 | $104,970170 claims |
| AstraZenecaBrilinta, Farxiga | $122 | $82,769134 claims |
| NovartisEntresto | $152 | $62,44881 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Greenville
- Paul MahoneyGreenville$1.7M
- Neeraj ShahGreenville$28K
- Muhammad TariqGreenville$16K
- George AdamsGarner$4.1M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
- Ronald UszenskiMooresville$495K
- Oluseun AlliCharlotte$485K
- Matthew CavenderChapel Hill$453K
- Steven FilbyPinehurst$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.